Low molecular weight IgM and CD5 B lymphocytes in rheumatoid arthritis

Huji Xu, Robin Geddes, Peter J Roberts-Thomson

Abstract

Objectives—To evaluate the role of low molecular weight (LMW) IgM and CD5 B cells in rheumatoid arthritis (RA) and to explore the possibility that LMW IgM is derived selectively from this subset of B cells.

Methods—LMW IgM in sera and culture supernatants was detected by a sensitive immunoblot technique with an enhanced chemiluminescence detection system. CD5 B cells were determined by FACScan cytometry. In vitro studies were established in culture plates containing pokeweed mitogen with or without 2-mercaptoethanol (2-ME). Supernatants were obtained from CD5 positive hybridomas and CD5 negative hybridomas. Other immunological indices were measured by laser nephelometry.

Results—Circulating LMW IgM was detected in all rheumatoid patients with significantly higher levels being observed in sero-positive patients. LMW IgM correlated significantly with total IgM and RF. Peripheral blood mononuclear cells (PBMC) from the majority of the patients with RA secreted LMW IgM in vitro as did mononuclear cells from a synovial fluid sample. The addition of low concentrations of 2-ME to the culture medium enhanced the proportions of secreted monomeric IgM. In contrast, PBMC from healthy subjects secreted only trace quantities of LMW IgM. In RA no significant correlations were observed between CD5 B cells and LMW IgM and RF. LMW IgM could be detected in the supernatants from both CD5+ and CD5–B cell lines. Finally, CD5 B cells were not significantly elevated in RA and levels remained constant over time.

Conclusion—LMW IgM exists in high concentrations in RA sera and synovial fluid. Serum level correlates with RF and IgM. In vitro studies have suggested that the occurrence of LMW IgM may be due to an intrinsic defect(s) in the assembly of the IgM pentameric molecule. LMW IgM is unlikely to be derived solely from CD5 B cells.

(*Ann Rheum Dis* 1994; 53: 383–390)

been described in high concentrations in four disease groups: (1) certain autoimmune diseases including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and primary biliary cirrhosis; (2) infective diseases such as chronic hepatitis B and subacute sclerosing panencephalitis; (3) immunodeficiency states such as selective IgA deficiency and ataxia telangiectasia; and (4) some B cell lymphoproliferative disorders, for example, chronic lymphocytic leukaemia (CLL) and Waldenström's macroglobulinaemia.⁴ Previous studies have shown a strong association between the levels of LMW IgM and the presence of rheumatoid vasculitis in RA and the severity of disease in RA and in SLE.^{2–4,5} Furthermore, a significant relationship has also been observed between LMW IgM and the total IgM levels, with levels of rheumatoid factor (RF) and with levels of circulating immune complexes in RA, primary biliary cirrhosis, infective endocarditis, and selective IgA deficiency etc.^{2–4,8} Its close association with indices of disease severity or activity suggests that LMW IgM may play an important role in the immunopathogenesis of those diseases. However, the functional activity of LMW IgM is poorly understood. Its cellular origins in vivo have not been explored.

The recent discovery that some auto-antibodies produced by mice and humans with genetically determined autoimmune disease are derived from CD5 B cells offers an exciting new avenue for investigation into the pathogenesis of human autoimmune diseases. CD5 B cells are lymphocytes that coexpress a 67-kDa pan T lymphocytes surface glycoprotein, designated CD5, and surface antigens restricted to the B lymphocyte lineage.⁹ CD5 B cells exist in varying proportions in discrete locations.⁹ They are present in fetal lymph nodes from 17 weeks of gestation and are also found in the peritoneal and pleural cavities and spleen.^{9–12} CD5 B cells are relatively abundant in early ontogeny but elevated levels of CD5 B cells have been found in the peripheral blood (PB) of patients with RA, Sjögren's syndrome and other autoimmune diseases.^{13–16} In humans, CD5 B cells constitute a component of the normal human B cell repertoire and are responsible for the production of IgM antibodies that react with multiple, structurally unrelated antigens, including the Fc fragment of human IgG (RF) and single stranded DNA.^{17–20} Moreover, it has been shown that CD5 B cells produces 2 types of RF: (1) a polyreactive and low affinity RF, produced by CD5 B cells of normal subjects and RA patients; (2) a monoreactive and high affinity RF, which is isolated only by CD5 B

Department of Clinical Immunology, Flinders Medical Centre, Flinders University of South Australia, South Australia

H Xu
R Geddes
P J Roberts-Thomson

Correspondence to:
A/Professor Peter Roberts-Thomson,
Department of Clinical Immunology, Flinders Medical Centre, Bedford Park, SA 5042, Australia.

Accepted for publication
7 March 1994

Low molecular weight (LMW) IgM is a naturally occurring monomeric form of circulating IgM.^{1,2} LMW IgM is found infrequently in healthy adult serum³ but has

cells from patients with RA.¹⁵ These studies therefore suggest CD5 B cells are involved in autoimmune responses. Whether they contribute to the pathogenesis of autoimmune disease is still uncertain.

In this current study we have evaluated the role of LMW IgM and CD5 B cell in RA. We are particularly interested to observe any correlation between these two variables as it is possible that CD5 B cells may be the cellular origin of LMW IgM in RA.

Materials and methods

PATIENTS AND CONTROLS

Thirty eight patients with RA participated in the study. All fulfilled the American Rheumatism Association revised criteria for RA, and 31 of the patients were seropositive. There were 27 women and 11 men with a mean (SD) age of 68.3 (11.7) years and a mean (SD) duration of disease of 13.2 (6.3) years. Eight patients with other inflammatory arthritides and three patients with osteoarthritis were also studied. Control subjects consisted of 17 healthy adults from the clinical and laboratory staff. Sera and PB from patients and controls were collected at the same time. Synovial fluid (SF) was also collected from one patient with RA.

CELL PREPARATION

Peripheral blood mononuclear cells (PBMC) and mononuclear cell from SF were separated by Ficoll-Hypaque sedimentation using standard techniques. Ten mL sample was mixed with 10 mL phosphate-buffered saline (PBS) and layered slowly onto 10 mL Lymphoprep (Nyegaard, Oslo). The tubes were then centrifuged at 750 g for 15 minutes. The mononuclear layer was removed into PBS and washed once. Any remaining red blood cells were lysed by incubating at room temperature for 5 minutes with 5 mL ammonium chloride lysing solution. The cells were then washed twice with PBS, and resuspended at 10^7 /mL in RPMI 1640 medium with 10% fetal calf serum for immunofluorescence staining and in-vitro study.

IMMUNOFLUORESCENCE STAINING CD5 B CELLS

Prepared PBMCs were mixed with both 20 μ L of FITC- anti-CD19 and the 20 μ L of PE-labelled anti-Leu-1 antibody (anti-CD5, Beckton Dickinson) for 30 minutes. In some cases, the cells were first incubated with 50 μ L of optimal diluted monoclonal antibody FMC63 (anti-CD19, Flinders Medical Centre) for 30 minutes. After washing twice, the cells were then incubated with 50 μ L of FITC-conjugated sheep antibody to mouse Ig F(ab) fragment (Silenus Laboratory, Victoria) for 30 minutes. Following washing and blocking using normal mouse serum, the cells were finally incubated with the 20 μ L of PE-labelled anti-Leu-1 antibody (anti-CD5, Beckton Dickinson) for 30 minutes. The cells were then washed three times and fixed. Fluorescence analysis was carried out using

FACScan flow cytometer (Beckton Dickinson, Mountain View, California) with standard settings. The efficacy of gating of the lymphocyte population was checked by the monocyte marker CD14 (FMC33, Flinders Medical Centre). The monoclonal antibody X-63 (negative control for lymphocytes, Flinders Medical Centre), FMC16 (positive control for lymphocytes, Flinders Medical Centre), OKT 3 (Pan-T-cell marker, American Type Culture Collection) were also used for control. For staining of X63, CD14, FMC16, and OKT3, the cells were first incubated with 50 μ L of the optimal diluted monoclonal antibodies, and then incubated with 50 μ L of FITC-conjugated sheep antibody to mouse Ig F(ab) fragment (Silenus Laboratory, Victoria) as described above. Ten thousand cells were analysed from each sample. The results were stored and analysed in list mode of lysis II program. To further analyse if the fluorescence distribution was unimodal or bimodal, 10 000 B cells were selected by live gating.

SECRETION OF LMW IgM IN VITRO

Cultures were established in 24 well flat-bottomed 2 mL culture plate containing 1×10^6 PBMCs or mononuclear cells from SF/mL and pokeweed mitogen (PMW, Gibco, Ohio USA) at a final dilution of 1:800 with or without 2-mercaptoethanol (2-ME) at 10^{-4} . Cultures were carried out in RPMI 1640 medium supplemented with penicillin G (200 U/mL), gentamicin (10 mg/mL), L-glutamine (0.3 mg/mL), and 10% fetal calf serum. The cells were incubated at 37°C in a humidified atmosphere of 5% CO₂ for three days, the supernatants collected, and then with fresh culture medium for further four days culture (two stages) or continuing seven days culture (without collecting the supernatants at day 3). The collected culture supernatants (total volume 20–30 mL) were concentrated in an Amicon ultrafiltration unit to a final volume of 300–400 μ L for LMW IgM quantitation. At day 7 the cell viability was determined.

CD5 HYBRIDOMAS CULTURE SUPERNATANTS

Culture supernatants from three CD5 positive hybridomas and two CD5 negative hybridomas were kindly provided by Dr C Brown (Division of Clinical Immunology, Kennedy Institute of Rheumatology, London). The hybridomas were established using in vivo activated B cells present in RA synovium immortalised by cell fusion using the heteromyeloma fusion partner, SPAZ-4. They all produced IgM. The supernatants (total volume 40–50 mL each) were concentrated in an Amicon ultrafiltration unit to a final volume 1–3 mL for further IgM size examination.

DETECTION OF LMW IgM

LMW IgM was detected by an enhanced chemiluminescence detection system combined with a modified immunoblot technique.²¹ In brief, serum and culture super-

Figure 1 Immunoblot appearance of RA sera containing variable levels of distinct monomeric IgM band (2×10^5 Da); the majority of them also having dimeric, trimeric and other oligomeric IgM in addition to the pentameric band (1×10^6 Da). Lane 1 is a purified IgM containing both HMW IgM and LMW IgM as standard control.

natant was separated on 3.6% SDS-PAGE and the separated serum proteins transferred to nitrocellulose, the IgM bands were developed with anti- μ , HRP-conjugated secondary antibody (Silenus Laboratory, Victoria) and binding finally detected by the enhanced chemiluminescence detection system (Amersham, UK) over 30 seconds. After immunoblotting, the blot was scanned using a Camag electrophoresis scanner and the areas subtended by the LMW IgM peak weighted and expressed in mg quantities.

OTHER IMMUNOLOGICAL METHODS
Serum IgM, RF and C reactive protein (CRP) were measured by laser nephelometry (Beckmans ICS). The interassay coefficients of variance for these measurements were 3.8%, 3.3% and 3.2%, respectively.

STATISTICAL ANALYSIS
The liner correlation method was used for the analysis of any correlations between two

variables. Comparison between patients and controls for LMW IgM and CD5 B cells were performed using the Student's *t* test. Significance was accepted if $p < 0.05$.

Results
LMW IgM IN THE SERA OF PATIENTS AND NORMAL CONTROLS
Sera from all patients and normal controls were examined for LMW IgM by the sensitive immunoblot method. In all patients' sera, distinct monomeric IgM bands were observed and in the majority of these dimeric, trimeric and other oligomeric IgM bands were also visible in addition to the pentameric band (fig 1). Among the patient groups, LMW IgM levels were significantly higher in sero-positive RA patients compared with sero-negative RA and other patients, ($p < 0.01$) (table 1). In contrast, LMW IgM was detected only in low level or trace quantities in the sera from normal controls as compared with patient group (table 1, the immunoblot for the normal controls not shown).

IN VITRO STUDIES
PBMC were prepared from 25 patients with RA, two with osteoarthritis and 12 normal controls. In addition, mononuclear cells from the SF from a patient with active RA was also used for in vitro studies. Using the immunoblot method, distinct LMW IgM bands were clearly revealed in the culture supernatants of 20 patients with RA and two patients with osteoarthritis whilst only four normal controls secreted trace amounts of monomeric and oligomeric IgM in addition to pentameric IgM (fig 2). Remarkably, LMW IgM accounted for 40.1% of the total secreted IgM from mononuclear cells from SF. In these cell culture experiments cell viability at day 7 was 96% with no differences being observed between patients and controls. There was no significant correlation between amount of LMW IgM in the sera and supernatant ($r = 0.2$, $p > 0.05$). Further studies found the addition of 2-ME to the cultures in final concentrations of 10^{-4} M resulted in the occurrence of increased quantities of monomeric and oligomeric IgM in the culture supernatant (fig 3). We have previously shown that this low concentration of 2-ME does not directly reduce secreted pentameric IgM to monomeric state in-vitro using the same experimental conditions as described above.²²

Table 1 Serological and cellular indices in patients

Patients and controls	Serological and cellular mean (SD) indices				
	LMW IgM (mg weight)	Total IgM (g/L)	CD5 B cells %	RF ¹	CRP ²
Sero-positive RA (n = 31)	279.3 (147.6)	1.69 (0.79)	35.0 (20.3)	365.1 (378.8)	24.6 (27.0)
Sero-negative RA (n = 7)	85.3 (47.5)	0.66 (0.67)	32.2 (10.7)	<30	23.9 (35.7)
Other inflammatory arthritides (n = 8)	144.4 (131.1)	1.38 (0.62)	41.6 (3.2)	155.0 (231.5)	9.4 (10.7)
Osteoarthritis (n = 3)	116.0 (46.7)	1.34 (0.91)	30.9 (22.3)	35.0 (8.6)	5.0 (2.8)
Normal controls (n = 17)	52.4 (28.9)	1.53 (0.82)	33.4 (9.3)	—	—

¹RF = Rheumatoid Factor, iu/mL (N<30)
²CRP = C Reactive Protein, mg/L (N<6)¹

Figure 2 Immunoblot appearance of culture supernatants from PMBCs (lane 1–7 and 9–15). One distinct monomeric IgM band (2×10^5 D) can be seen in lane 2–7, 9–10 and 12 in addition to the pentameric band (1×10^6 D). Lane 8 is a purified IgM containing both HMW IgM and LMW IgM as standard control. Note: the chemiluminescence reaction was visualised by exposure of the NC to radiographic film for 30 minutes.

Figure 3 (A) Immunoblot appearance of the supernatants from an *in vitro* study: 1) without 2-ME in culture medium; 2) with 2-ME in culture medium. An arrow indicates the band of LMW IgM. (B) Densitometric profiles of PBMC culture supernatants with corresponding A. Enhanced secretion of LMW IgM and other oligomeric IgM from PBMC with 2-ME in culture medium was noted.

CD5 B CELLS IN RA AND NORMAL CONTROLS

Using FACScan flow cytometry and two-colour fluorescence, CD5 B cells were enumerated in the PB of patients and controls. A comparison of the percentage of CD5 B cell in the different study groups is shown in fig 4. An increased mean (SD) percentage of CD5 B cells in sero-positive RA [35.0 (20.3)] and other inflammatory arthritides [41.6 (3.2)], and a decreased percentage in sero-negative RA [32.2 (10.7)] and osteoarthritis [30.9 (22.3)] was observed, when compared with normal controls [33.4 (9.3)]. These differences however were not significant (table 1).

CD5 B cells were measured in eight patients with RA and two with other inflammatory

Figure 4 Percentages of CD5 B cells in patients with RA, osteoarthritis and other inflammatory arthritides and normal controls. There is an increased mean (SD) percentage of CD5 B cells in sero-positive RA (SPRA) [35.0% (20.3)] and other inflammatory arthritides (OIA) [41.6% (3.2)], and a decreased mean (SD) percentage in sero-negative RA (SNRA) [32.2% (10.7)], osteoarthritis [30.9% (22.3)], compared with normal controls [33.4 (9.3)]. However, these differences are not significant.

arthritides for more than two occasions over a one year period. CD5 B cells remained constant in these patients despite different disease activity or treatment regime (table 2). Studies of CD5 B cells in a small group of normal controls with different ethnic backgrounds, found that Chinese subjects had significantly higher levels than white subjects [41.2% (10.6) *v* 33.4% (9.3), $p < 0.01$].

To analyse if the fluorescence distribution of the CD5 antigen was unimodal or bimodal, 10 000 B cells were selected by live gating. It was shown that there were three populations of B cells, with the majority of B cells unstained, a small number of cells briefly stained for CD5 and a few intermediate staining cells. There was a significant low level of highly stained CD5 B cells in RA compared with controls (1.7% *v* 4.0%) (fig 5).

CORRELATION BETWEEN LMW IgM, CD5 B CELLS AND OTHER IMMUNOLOGICAL INDICES

Significant correlations were noted between LMW IgM and total IgM in RA (both sero-positive and negative. $r = 0.76$, $r = 0.94$, $p < 0.05$, respectively), but not in patients with other inflammatory arthritides ($r = 0.41$, $p > 0.05$) and osteoarthritis patients ($r = 0.46$, $p > 0.05$). Significant correlations were also observed in LMW IgM and RF in sero-positive RA ($r = 0.49$, $p < 0.05$) (fig 6). However, there were no significant correlations between total IgM and CD5 B cells ($r = 0.018$, $p > 0.05$), LMW IgM and CD5 B cells ($r = 0$, $p > 0.05$), RF and CD5 B cells ($r = 0$, $p > 0.05$), and CRP and CD5 B cells ($r = 0.016$, $p > 0.05$) in Sero-positive RA and all other patient groups (fig 6).

LMW IgM IN SUPERNATANTS FROM IgM SECRETING B CELL LINES

To explore the cellular origins of LMW IgM in RA, CD5 B cell lines were cultured and the

Table 2 CD5 B cells in patients over time

Patients	Sex/age	Diagnosis	Disease duration	Disease activity	Drug regime	Tested date	CD5 B cells%
1	F/71	SPRA	20 years	Active	Meth	01/07/91	31.8
2	F/60	SPRA	39 years	Active	None	07/10/91	32.2
				Active	Meth	01/07/91	68.6
3	F/71	SPRA	10 years	Active	Meth	09/09/91	70.7
				Active	Imuran/Pred	15/07/91	25.8
4	F/29	SPRA	4 years	Active	Pred	11/11/91	23.9
				Active	Pred/Plaq	21/10/91	40.6
5	F/59	SPRA	18 years	Active	Pred/Plaq	16/03/92	56.1
				Active	None	09/03/92	40.1
6	F/81	SPRA	>10 years	Active	Gold/Plaq/Pred	15/06/92	31.2
				Inactive	None	04/05/92	10.9
7	M/62	SPRA	6 years	Active	Pred	06/07/92	9.8
				Active	None	04/05/92	30.4
8	M/69	SNRA	8 years	Active	Meth	06/07/92	25.5
				Inactive	Meth	08/07/91	23.3
9	F/88	OIA	1 year	Active	Meth	06/07/92	28.9
				Active	Sala/Pred	01/07/91	57.5
10	M/24	OIA	5 years	Inactive	None	04/11/91	38.8
				Active	Plaq	15/07/91	47.2
				Active	Thyroxine	04/11/91	45.0

SPRA: Sero-positive RA; SNRA: Sero-negative RA; OIA: Other inflammatory arthritides, Meth: Methotrexate; Imuran: Azathioprine; Pred: Prednisone; Plaq: Plaquenil; Sala: Salazopyrin.

supernatants examined for IgM size. It was shown that LMW IgM could be detected in the supernatants from both CD5+ and CD5- B cell lines (fig 7).

Discussion

Using our sensitive chemiluminescence detection system we have shown that LMW IgM existed in all our patients with RA and significant higher levels was found in the sero-positive patients (fig 1, table 1). Furthermore, a significant correlation was noted between LMW IgM and RF in these patients (fig 6).

The significance of LMW IgM in these sera is unknown. LMW IgM has been detected in both sera and SF of the patients with RA but not SF from other inflammatory arthritides.^{2 23 24} Anderson-Imbert²³ reported that the concentrations of LMW IgM in SF always exceeded that of the corresponding sera, but Roberts-Thomson *et al*,² found that only two of 10 RA SF had higher LMW IgM levels than the corresponding sera, implying the local synovial membrane synthesis of LMW IgM. This is confirmed in our in vitro study which showed that secreted LMW IgM was found

from mononuclear cells from the SF of a patient with RA and the amount of LMW IgM accounted for 40.1% of the total secreted IgM. This finding provides direct evidence that LMW IgM can be synthesised in pathogenic joints.

The mechanism(s) for the occurrence of LMW IgM in human disease are still uncertain. Previous reports clearly showed that LMW IgM was not the product of pentameric IgM metabolism in vivo and not derived from membrane-bound IgM as well.⁴ In this study we found a significant correlation between the levels of circulating LMW IgM and total IgM (fig 6); the presence of LMW IgM with other LMW oligomers of IgM (fig 1); and the secretion of LMW IgM from PBMC in vitro (fig 2). All these findings suggest that LMW IgM may be released into circulation due to a defect of assembly of the IgM pentameric molecule. This could be a deficiency in any of the multiple steps involved in IgM polymerisation. However, in these steps J chain and glycosylation of μ heavy chain is not required for IgM polymerisation, per se.²⁵ In this study we showed the addition of low quantities of 2-ME to the culture medium could enhance

Figure 5 Histogram depicting B cells (selected using anti-CD19 staining together with forward and side-scatters) staining with CD5 antibody. Three populations of CD5 B cells were observed. There was a significant low level of highly stained CD5 B cells in RA compared with controls (1.7% v 4.0%).

Figure 6 Correlations between LMW IgM, CD5 B cells and other immunological indices in sero-positive RA. Significant correlations were noted only between LMW IgM and total IgM (A: $r = 0.76$, $p < 0.05$), and LMW IgM and RF (B: $r = 0.46$, $p < 0.05$). There were no significant correlations between total IgM and CD5 B cells (C: $r = -0.018$, $p > 0.05$), LMW IgM and CD5 B cells (D: $r = 0$, $p > 0.05$), RF and CD5 B cells (E: $r = 0$, $p > 0.05$), and CRP and CD5 B cells (F: $r = 0.016$, $p > 0.05$).

the secretion of LMW IgM from PBMC in vitro (fig 3). Our more recent experiment using a JVM3 cell line and others using a B lymphoma cell line have observed the same finding.²²⁻²⁶ This raises the possibility that alteration in the redox potential of the cellular microenvironment or the provision of free-SH radicals which might interrupt interchain disulphide bonds might be important. It is known that IgM polymerisation is catalysed by two protein enzymes—protein disulphide isomerase and protein disulphide oxidoreductase.²⁷⁻²⁸ Protein disulphide isomerase has multiple roles in the modification of nascent secretory proteins.²⁷ Protein disulphide oxidoreductase, on the other hand, is identified to be a B lymphocyte specific enzyme that catalyses pentamer IgM assembly.²⁸ The addition of 2-ME to the culture medium could

Figure 7 LMW IgM in CD5+ and CD5- B cell line culture supernatants. Lane 1-3 are CD5+ cell lines culture supernatants. Lane 4-5 are CD5- cell lines culture supernatants. Lane 6 is a positive control serum. Lane 7 is a normal human serum. LMW IgM could be detected in the supernatants from both CD5+ and CD5- B cell lines.

interfere with the functional activity of this enzyme or the sulphhydryl radicals of the cysteine involved in inter-chain disulphide links. It is found that cysteine in μ tailpiece plays a crucial role in the polymerisation of IgM.²⁹ Thus molecular cloning and the characterisation of disulphide oxidoreductase should ultimately shed some insight into the gene regulation of polymerisation of IgM and provide basic insights into the mechanism underlying development and differentiation of B lymphocytes in human disease.

Whether LMW IgM is derived from a specific subset of B lymphocytes has not been previously explored. We therefore focused our investigation on CD5 B cells. Previous studies have found that LMW IgM commonly occurs in four disease groups.⁴ Coincidentally, in these diseases there invariably exist higher levels of circulating CD5 B cells or activated CD5 B cells.^{14-16, 17, 19, 21, 30} CD5 B cells are responsible for the production of high affinity RF in RA.¹⁵ Furthermore, LMW IgM and CD5 B cells from patients with RA shared the same major RF cross-reactive idiotype.³¹ These data indirectly suggest that LMW IgM may come from CD5 B cells. However, in this study no significant correlation was found between LMW IgM and CD5 B cells in patients with RA (fig 6). In vitro study showed that variable levels of LMW IgM could be detected in PBMC from the majority of patients with RA. Furthermore, LMW IgM could be detected in the supernatants from both CD5+ and CD5- B cell lines (fig 7). This study therefore suggests that LMW IgM is unlikely to be derived solely from CD5 B cells.

We also addressed the question of the role of CD5 B cells in RA. We found increased percentages of CD5 B cells in RA (fig 4), however, these differences were not significant compared with healthy controls (table 1). The increased frequency of CD5 B cells in RA blood was initially reported by Plater-Zyberk *et al*, in 1985¹³ and observed by others,^{9 15 17 32} but not all reports have confirmed these findings.^{33 34} These controversial results may be due to a number of reasons, including the wide differences in the epitope density of CD5 on the B cell membrane, patient sampling, drug regime, and the different sensitivities of the methods used. Our study found different epitope density of CD5 on the B cells with three populations of CD5 B cells being observed (fig 5). The significance of this bimodal fluorescence distribution in CD5 B cells is unknown but it appeared that the increased CD5 B cells in RA are the intermediate staining cells. Methods with different sensitivities for the detection of CD5 B cells give rise to the different levels of CD5 B cells in the circulation. For example, using fluorescence-microscopic techniques, CD5 B cells were found to comprise an average of 20% of the circulating B cells of patients with RA compared with less than 5% of the B cells of normal controls.¹³ However, Dauphine *et al*, using a sensitive flow-cytometric technique, reported that 46% of rheumatoid B cells were CD5 positive compared with 20% CD5 B cells in normal controls.³⁵ Another report showed the control group of individuals in which the proportions of CD5 B cells rose from <5% when detected by microscopy to 19.5% when identified by the FACstar cytometry.³⁶ In comparative evaluation CD5 B cells in RA patients using FACS analyser and FACScan, different levels of CD5 B cells have been found in the same patient's sample.³⁷ As such, more sensitive techniques have resulted in smaller differences in the proportions of CD5 B cells in RA and normal controls.

Our data showed the levels of CD5 B cells in the PB of patients with RA and other inflammatory arthritides were stable over time (table 2). This finding has been supported by other investigations.^{16 38 39} The exception was patients treated with high-dose corticosteroids or combined immunosuppressive chemotherapy and irradiation.^{16 39} However, there appears to be no clear correlation between the numbers of CD5 B cells and the therapy.⁴⁰ The increase of CD5 B cells also appears to be independent of disease activity in juvenile arthritis.⁴¹ The proportion of circulating B cells that express CD5 appears to be relatively constant in any given individual.³⁸ A recent study found that elevated levels of CD5 B cells were a distinctive feature of selected families with RA, rather than a peculiarity of patients with RA compared with their healthy relatives.³² Moreover, monozygotic twins discordant for RA have identical levels of CD5 B cells.³⁸ Thus these data suggest that the expression of CD5 on B cells, within the framework of RA is, at least partly, genetically determined. This conclusion is further

supported by our finding that CD5 B cells are higher in certain ethnic groups such as Chinese. This finding is consistent with another report that Japanese have elevated levels of CD5 B cells.⁴²

In the present study no significant correlations were observed between CD5 B cells and other immunological indices including RF (fig 6). Several studies have also shown no apparent relationship between the relative CD5 B cell levels and the titre of RF,^{13 38} except for patients with extremely high titres ($>5 \times 10^{12}$) of RF.³⁹ Moreover, not all patients with RA have high levels of CD5 B cells, and normal unaffected individuals without RF may have high levels of CD5 B cells.^{17 38 43}

What is the role of CD5 B cells in the pathophysiology of RA? The answer is still uncertain. Perhaps these uncertainties are secondary to the fact that the population of circulating lymphocytes in the PB is not representative of the cells found at sites of primary disease activity such as the peripheral joints. A study has already demonstrated that percentages of CD5 B cells in patients with RA were significantly higher in SF compared with that in PB.³³ A closer examination of the cells and autoantibodies secreted within these sites may therefore reveal a more definitive relationship between the CD5 B cells and autoimmune diseases.

Dr Huji Xu is an Australian National Health and Medical Research Council (NH&MRC) Visiting and Postgraduate Scholar. This work is supported by grants from the Arthritis Foundation of Australia and NH and MRC for the scholarship.

- Harisdangkul V, McDougal J S, Knapp M, Christian C L. Naturally occurring low molecular weight IgM in patients with rheumatoid arthritis, systemic lupus erythematosus and macroglobulinemia. I. Purification and immunologic studies. *J Immunol* 1975; **115**: 216-22.
- Roberts-Thomson P J, Wernick R M, Ziff M. Low molecular weight IgM in rheumatoid arthritis and other rheumatic diseases. *Arthritis Rheum* 1981; **24**: 795-802.
- Harris R, Beckman I, Roberts-Thomson. Low molecular weight IgM: detection using immunoblotting. *J Immunol Methods* 1986; **88**: 97-100.
- Xu H J, Roberts-Thomson P J. Circulating low molecular weight IgM—A disease marker in autoimmune, infective, immunodeficient and B cell lymphoproliferative disorders. *Disease Markers* 1992; **10**: 115-41.
- Harisdangkul V, Barnes T Y, Sogcharoen S, Pennebaker J B. Clinical significance of low molecular weight IgM in patients with systemic lupus erythematosus. *J Rheumatol* 1984; **11**: 638-43.
- Fakunle Y M, Aranguibel F, DeVilliers D, Thomas H C, Sherlock S. Monomeric (7s) IgM in chronic liver diseases. *Clin Exp Immunol* 1979; **38**: 204-10.
- Koh L Y, Jones D N, Roberts-Thomson P J. Appearance of low molecular weight IgM during course of infective endocarditis. *Clin Exp Immunol* 1986; **64**: 471-5.
- Kwitko A, Roberts-Thomson P J, Shearman D J C. Low molecular weight IgM in selective IgA deficiency. *Clin Exp Immunol* 1982; **50**: 198-202.
- Kipps T J. The CD5 B cell. *Adv Immunol* 1989; **47**: 117-85.
- Ledberter J A, Clark E A. Surface phenotype and function of tonsillar germinal center and mantle zone B cell subsets. *Human Immunol* 1986; **15**: 30-43.
- Bofill M, Janossy G, Janossa M, *et al*. Human B cell development II. Subpopulations in the human fetus. *J Immunol* 1985; **134**: 1531-38.
- Antin J H, Emerson S G, Martin P, Gadol N, Adult K A. Leu-1+ (CD5+) B cell. A major lymphoid subpopulation in human fetal spleen: Phenotype and functional studies. *J Immunol* 1986; **136**: 505-10.
- Plater-Zyberk C, Maini R N, Lam K, Kennedy T D, Janossy G. A rheumatoid arthritis B cell subset expresses a phenotype similar to that in chronic lymphocytic leukemia. *Arthritis Rheum* 1985; **28**: 971-6.
- Lydyard P M, Youinou P Y, Cooke A. CD5-positive cells in rheumatoid arthritis and chronic lymphocytic leukemia. *Immunol Today* 1987; **8**: 37-9.
- Burastero S E, Cassali P, Wider R L, Notkins A L. Monoreactive high affinity and polyreactive low affinity rheumatoid factors are produced by CD5+ B cells from patients with rheumatoid arthritis. *J Exp Med* 1988; **168**: 1979-92.

- 16 Dauphinee M, Tovar Z, Talal N. B cells expressing CD5 are increased in Sjogren's syndrome. *Arthritis Rheum* 1988; **31**: 642-7.
- 17 Hardy R R, Hayakawa K, Shimizu M, Yamasaki K, Kishimoto T. Rheumatoid factors secretion from human Leu-1+ B cells. *Science* 1987; **236**: 81-3.
- 18 Casali P, Burastero S, Nakamura M, Inghirami G, Notkins A L. Human lymphocytes making rheumatoid factors and antibodies to single stranded DNA belong to the Leu-1+B cell subset. *Science* 1987; **236**: 77-81.
- 19 Casali P, Notkins A L. Probing the human B-cell repertoire with EBV: polyreactive antibodies and CD5+ B lymphocytes. *Ann Rev Immunol* 1988; **7**: 513-35.
- 20 Casali P, Burastero S, Balow J E, Notkins A L. High-affinity antibodies to ssDNA are produced by CD5 B cells in systemic lupus erythematosus patients. *J Immunol* 1989; **143**: 3476-83.
- 21 Xu H J, Umapathysivam K, McNeilage J, Gordon T P, Roberts-Thomson P J. An enhanced chemiluminescence detection system combined with a modified immunoblot technique for the detection of low molecular weight IgM in sera from healthy adults and neonates. *J Immunol Methods* 1992; **146**: 241-7.
- 22 Xu H J, Roberts-Thomson P J. Low molecular weight IgM in the sera of patients with chronic lymphocytic leukemia. *Pathology* 1993; **25**: 52-6.
- 23 Anderson-Imbert A, Harisdangkul V, Debracco M, Christian C L. Low molecular weight IgM in rheumatoid synovial fluid. *Arthritis Rheum* 1972; **15**: 426.
- 24 Ezaki I, Shingu M, Nobunaga M, Otsuka E. Detection of low molecular weight IgM by immunoblot analysis in rheumatoid arthritis. *J Rheumatol* 1987; **14**: 674-9.
- 25 Davis A C, Shulamn M J. IgM-Molecular requirements for its assembly and function. *Immunol Today* 1989; **10**: 118-28.
- 26 Alberini C M, Bet P, Mistein C, Sitia R. Secretion of immunoglobulin M assembly intermediates in the presence of reducing agents. *Nature* 1990; **347**: 485-7.
- 27 Freedman R B. Protein disulfide isomerase: multiple role in the modification of nascent secretory proteins. *Cell* 1989; **57**: 1069-72.
- 28 Roth R, Koshland M E. Identification of a lymphocyte enzyme that catalyses pentamer immunoglobulin M assembly. *J Bio Chem* 1981; **256**: 4633-9.
- 29 Sita R, Neuberger M, Alberini C, et al. Developmental regulation of IgM secretion: the role of the carboxy-terminal cysteine. *Cell* 1990; **60**: 781-90.
- 30 Suzuki N, Sakene T, Engleman. Anti-DNA antibody production of CD5+ and CD5- B cells of patients with systemic lupus erythematosus. *J Clin Invest* 1990; **85**: 238-47.
- 31 Bongura V R, Pernis B, Agostino N, Ilowite N T, Hatam L, Wedgwood J R. The major rheumatoid factor cross-reactive idiotype in rheumatic disease. *Int Rev Immunol* 1989; **5**: 139-51.
- 32 Youinou P, Mackenzie L, Katskis P, et al. The relationship between CD5-expressing B lymphocytes and serologic abnormalities in rheumatoid arthritis and their relatives. *Arthritis Rheum* 1990; **33**: 339-48.
- 33 Sowden J A, Roberts-Thomson P J, Zola H. Evaluation of CD55-positive B cells in blood and synovial fluid of patients with rheumatic diseases. *Rheumatol Int* 1987; **7**: 255-9.
- 34 Smalley H B, Todd J, Barnes R M, Thompson R N, Abraham G N, Jonson P M. Estimation of serum V Kappa III light chains in rheumatoid arthritis and correlation with CD5-positive B-cells. *Br J Rheumatol* 1990; **29**: 325-30.
- 35 Dauphinee M, Kincaid W, Talal N. Increased incidence of B cells coexpressing a T cells marker in rheumatoid arthritis. *Sixth International Congress of Immunology* (abstr) 3, 12, 9.
- 36 Plater-Zyberk C, Maini R N. Phenotypic and functional features of CD5+ B lymphocytes in rheumatoid arthritis. *Scand J Rheumatol* 1988; **75** (suppl): 73-83.
- 37 Xu H J, Roberts-Thomson P J, Ahern M J, Zola H. Comparative evaluation of CD5 B cells in patients with rheumatoid arthritis and essential mixed cryoglobulinemia using FACS analyzer and FACScan flow cytometer. *Ann NY Acad Sci* 1992; **651**: 594-8.
- 38 Kipps T J, Vaughan J H. Genetic influence on the levels of circulating CD5 B lymphocytes. *J Immunol* 1987; **139**: 1060-4.
- 39 Taniguchi O, Miyajima H, Hirano T, et al. The Leu-1 B cell subpopulation in patients with rheumatoid arthritis. *J Clin Immunol* 1987; **7**: 441-8.
- 40 MacKenzie M R, Paglieroni T G, Warner N L. Multiple myeloma: An immunological profile. IV. The EA rosette-forming cell is a Leu-1 positive immunoregulatory B cell. *J Immunol* 1987; **139**: 24-8.
- 41 Martini A, Massa M, De Benedetti F, Viola S, Neirrotti G, Burgio R G. CD5 positive B lymphocytes in seronegative juvenile arthritis. *J Rheumatol* 1990; **17**: 932-5.
- 42 Hardy R R, Hayakawa K. Development and Physiology of Ly-1 B and its human homology Leu-1 B. *Immunol Rev* 1987; **93**: 53-81.
- 43 Maini R N, Plater-Zyberk C, Andrew E. Autoimmunity in rheumatoid arthritis. An approach via a study B lymphocytes. *Rheum Dis Clin North Am* 1987; **13**: 319-38.